3.57
-0.22(-5.80%)
Currency In USD
| Previous Close | 3.79 |
| Open | 3.85 |
| Day High | 3.85 |
| Day Low | 3.55 |
| 52-Week High | 6.6 |
| 52-Week Low | 1 |
| Volume | 123,393 |
| Average Volume | 350,158 |
| Market Cap | 34.12M |
| PE | -2.29 |
| EPS | -1.56 |
| Moving Average 50 Days | 3.96 |
| Moving Average 200 Days | 2.76 |
| Change | -0.22 |
If you invested $1000 in SAB Biotherapeutics, Inc. (SABS) since IPO date, it would be worth $35.17 as of February 22, 2026 at a share price of $3.57. Whereas If you bought $1000 worth of SAB Biotherapeutics, Inc. (SABS) shares 3 years ago, it would be worth $532.84 as of February 22, 2026 at a share price of $3.57.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
GlobeNewswire Inc.
Jan 07, 2026 1:00 PM GMT
David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a full
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today annou
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
Enrollment in the SAFEGUARD trial is ongoing at multiple centers globallyCompany on-track to share Phase 2b data in 2H 2027 MIAMI, Dec. 18, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical compan